EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

X Le,A Eisert,U Himpe,C De Bondt,J Mazieres,I Petrini,L.M Tho,A Ahmad,W.-S Lam,Y.K.J Chik,W.C.K Lee,T.-Y Yang,K Joshi,K Berghoff,S Vlassak,N Karachaliou,A.V.D Wekken

doi:10.1016/j.jtho.2022.07.845

EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series

X Le, A Eisert + Show 15 more

Open Access

https://doi.org/10.1016/j.jtho.2022.07.845

Copy DOI

Journal: Journal of Thoracic Oncology	Publication Date: Sep 1, 2022
Citations: 4

Affiliation: The University of Texas MD Anderson Cancer Center, Integrated Oncology (United States), Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, Antwerp University Hospital, Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Azienda Ospedaliera Universitaria Pisana, Hospital Kuala Lumpur, Beacon College, Queen Elizabeth Hospital, Prince of Wales Hospital, Taichung Veterans General Hospital, Imperial Consultants, University Medical Center Groningen

#Progression-free Survival Hazard Ratio #EGFR-TKI Gefitinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

MET amplification (METamp) is a mechanism of acquired resistance to EGFR-TKIs. In INSIGHT (NCT01982955; data cut-off: September 3, 2021), the combination of tepotinib (a potent, highly selective MET-TKI) and the EGFR-TKI gefitinib (n=12) improved outcomes compared with chemotherapy (n=7) in patients with EGFR-mutant METamp NSCLC and EGFR-TKI resistance (progression-free survival hazard ratio [HR]=0.13, 90% confidence interval [CI]: 0.04, 0.43; overall survival HR=0.10, 90% CI: 0.02, 0.36). Tepotinib combined with an EGFR-TKI may therefore overcome MET-related EGFR-TKI resistance.

Full Text